Management of Antiphospholipid Syndrome in Pregnancy
Women with obstetric APS planning pregnancy should receive combined low-dose aspirin (81-100 mg daily) plus prophylactic-dose LMWH starting after pregnancy confirmation, while those with thrombotic APS require therapeutic-dose LMWH plus aspirin throughout pregnancy and postpartum. 1
Preconception Risk Stratification
Before conception, identify the specific APS subtype as this determines treatment intensity:
High-risk features include:
- Lupus anticoagulant positivity (RR 12.15 for adverse outcomes) 1
- Triple-positive aPL (all three antibodies positive)
- History of thrombotic events
- Coexisting SLE
- Previous pregnancy complications despite treatment 2
Test for all three antibodies (lupus anticoagulant, anticardiolipin, anti-β2GPI) once before or early in pregnancy—do not repeat during pregnancy as titers remain stable 1.
Treatment Algorithm by APS Category
1. Obstetric APS (history of pregnancy loss/complications, no thrombosis)
Standard therapy (strong recommendation):
- Low-dose aspirin 81-100 mg daily starting preconceptionally
- Prophylactic-dose LMWH after pregnancy confirmation
- Continue both through delivery 1
Consider adding hydroxychloroquine for primary APS—recent studies suggest reduced complications, though this is a conditional recommendation 1
2. Thrombotic APS (history of blood clots)
Mandatory therapy (strong recommendation):
- Low-dose aspirin 81-100 mg daily
- Therapeutic-dose LMWH (not prophylactic dose) throughout pregnancy and postpartum
- Switch from warfarin to LMWH immediately upon pregnancy confirmation 1
Warfarin can restart 4-6 hours after vaginal delivery or 6-12 hours after cesarean section 3.
3. Asymptomatic aPL-positive (no prior thrombosis or pregnancy loss)
Conditional recommendation:
- Prophylactic aspirin 81-100 mg daily starting before 16 weeks gestation for preeclampsia prevention
- Continue through delivery
- LMWH generally not recommended unless additional high-risk features present (triple-positive aPL, strongly positive LAC, advanced maternal age, IVF pregnancy) 1
Essential Monitoring During Pregnancy
- Blood pressure monitoring at each visit (critical for detecting preeclampsia) 2
- Doppler ultrasonography and biometric parameters, particularly third trimester, to screen for placental insufficiency and fetal growth restriction 2
- If coexisting SLE: monitor disease activity, renal function, complement levels (C3/C4), anti-dsDNA at least once per trimester 2, 1
Management of Refractory Cases
Despite standard therapy, 25% of obstetric APS pregnancies still experience loss 1. For treatment failures:
Do NOT use (strong recommendations against):
- Increased LMWH doses—no demonstrated benefit 1
- Intravenous immunoglobulin—only anecdotal support 1
- Prednisone addition—no controlled studies showing benefit and increases maternal/fetal risks 1
May consider in select cases:
- Hydroxychloroquine addition (conditional recommendation) 1
- Therapeutic-dose heparin instead of prophylactic
- Low-dose prednisolone in first trimester only (limited evidence) 4
Critical Pitfalls to Avoid
Do not use rivaroxaban or other DOACs in APS patients, especially those with triple-positive antibodies—associated with increased thrombotic events 4.
Timing matters: Aspirin must start early (before 16 weeks) for preeclampsia prevention efficacy 1. Starting later provides minimal benefit.
Distinguish lupus nephritis flare from preeclampsia: Both present with hypertension and proteinuria. Check complement levels, anti-dsDNA, urinary sediment, and platelet count—active nephritis shows low complements, rising anti-dsDNA, and active urinary sediment 1.
Postpartum Management
Continue anticoagulation for 6-12 weeks postpartum as thrombotic risk remains elevated. Women with thrombotic APS should resume long-term anticoagulation (warfarin acceptable postpartum) 3.
The 2020 ACR guidelines 1 represent the most recent high-quality evidence and supersede older recommendations, providing the strongest framework for these management decisions.